Altered reactivity to norepinephrine through COX-2 induction by vascular injury in hypercholesterolemic rabbits

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 297, Issue 5, 2009, Pages

  Foudi, Nabil ^a,b   Norel, Xavier ^a   Rienzo, Mario ^a   Louedec, Liliane ^a   Brink, Charles ^a   Michel, Jean Baptiste ^a   Bäck, Magnus ^a,c  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atherosclerosis; Cyclooxygenase; Eicosanoids; Prostaglandins; Vascular reactivity

Indexed keywords

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; CYCLOOXYGENASE 2; INDOMETACIN; NORADRENALIN; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; THROMBOXANE A2;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY TONE; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; BLOOD VESSEL REACTIVITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; RABBIT;

6-KETOPROSTAGLANDIN F1 ALPHA; ANIMALS; AORTA, ABDOMINAL; AORTIC DISEASES; ATHEROSCLEROSIS; CHOLESTEROL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; EPOPROSTENOL; HYPERCHOLESTEROLEMIA; INDOMETHACIN; MALE; NOREPINEPHRINE; RABBITS; THIOPHENES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 70350455495     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00092.2009     Document Type: Article

References (32)

1. Adeagbo AS, Zhang X, Patel D, Joshua IG, Wang Y, Sun X, Igbo IN, Oriowo MA. Cyclo-oxygenase-2, endothelium and aortic reactivity during deoxycorticosterone acetate salt-induced hypertension. J Hypertens 23: 1025-1036, 2005. (Pubitemid 40637922)
2. Bäck M. Inflammatory signaling through leukotriene receptors in atherosclerosis. Curr Atheroscler Rep 10: 244-251, 2008.
3. Bäck M, Norel X, Walch L, Gascard J, de Montpreville V, Dahlen S, Brink C. Prostacyclin modulation of contractions of the human pulmonary artery by cysteinyl-leukotrienes. Eur J Pharmacol 401: 389-395, 2000. (Pubitemid 30608724)
4. Balazy M, Brass EP, Gerber JG, Nies AS. Facile method for preparation of 2,3-dinor-6-keto PGF1 alpha, the major urinary metabolite of prostacyclin. Prostaglandins 36: 421-430, 1988. (Pubitemid 19009200)
5. Beetens JR, Coene MC, Verheyen A, Zonnekeyn L, Herman AG. Biphasic response of intimal prostacyclin production during the development of experimental atherosclerosis. Prostaglandins 32: 319-334, 1986. (Pubitemid 17183334)
6. Berberian PA, Jenison MW. Arterial prostaglandins and lysosomal function during atherogenesis. I. Homogenates of diet-induced atherosclerotic aortas of rabbit. Exp Mol Pathol 43: 22-35, 1985. (Pubitemid 15242053)
7. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1528, 2000. (Pubitemid 30844348)
8. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102, 2005. (Pubitemid 40365350)
9. Bull HA, Rustin MH, Spaull J, Cohen J, Wilson-Jones E, Dowd PM. Pro-inflammatory mediators induce sustained release of prostaglandin E2 from human dermal microvascular endothelial cells. Br J Dermatol 122: 153-164, 1990. (Pubitemid 20069115)
10. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 104: 921-927, 2001. (Pubitemid 32778044)
11. El-Haroun H, Bradbury D, Clayton A, Knox AJ. Interleukin-1beta, transforming growth factor-beta1, and bradykinin attenuate cyclic AMP production by human pulmonary artery smooth muscle cells in response to prostacyclin analogues and prostaglandin E2 by cyclooxygenase-2 induction and downregulation of adenylyl cyclase isoforms 1, 2, and 4. Circ Res 94: 353-361, 2004. (Pubitemid 38240727)
12. Foudi N, Kotelevets L, Louedec L, Leseche G, Henin D, Chastre E, Norel X. Vasorelaxation induced by prostaglandin E(2) in human pulmonary vein: role of the EP(4) receptor subtype. Br J Pharmacol 154: 1631-1639, 2008.
13. Foudi N, Louedec L, Cachina T, Brink C, Norel X. Selective COX-2 inhibition directly increases human vascular reactivity to norepinephrine during acute inflammation. Cardiovasc Res 81: 269-277, 2009.
14. Garavito RM, Malkowski MG, DeWitt DL. The structures of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat 68-69: 129-152, 2002.
15. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116: 4-15, 2006. (Pubitemid 43121782)
16. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6: 508-519, 2006. (Pubitemid 43980523)
17. Hernandez-Presa MA, Martin-Ventura JL, Ortego M, Gomez-Hernandez A, Tunon J, Hernandez-Vargas P, Blanco-Colio LM, Mas S, Aparicio C, Ortega L, Vivanco F, Gerique JG, Diaz C, Hernandez G, Egido J. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 160: 49-58, 2002. (Pubitemid 34082716)
18. Hlawaty H, Jacob MP, Louedec L, Letourneur D, Brink C, Michel JB, Feldman L, Bäck M. Leukotriene receptor qntagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arterioscler Thromb Vasc Biol 29: 518-524, 2009.
19. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363: 1751-1756, 2004. (Pubitemid 38698377)
20. Moreland KT, Procknow JD, Sprague RS, Iverson JL, Lonigro AJ, Stephenson AH. Cyclooxygenase (COX)-1 and COX-2 participate in 5,6-epoxyeicosatrienoic acid-induced contraction of rabbit intralobar pulmonary arteries. J Pharmacol Exp Ther 321: 446-454, 2007.
21. Norel X. Prostanoid receptors in the human vascular wall. Scientific- WorldJournal 7: 1359-1374, 2007. (Pubitemid 47435435)
22. Norel X, Walch L, Gascard JP, de Montpreville V, Brink C. Prostacyclin release and receptor activation: differential control of human pulmonary venous and arterial tone. Br J Pharmacol 142: 788-796, 2004. (Pubitemid 38969674)
23. Qi W, Wei JX, Dorairaj I, Mahajan RP, Wilson VG. Evidence that a prostanoid produced by cyclo-oxygenase-2 enhances contractile responses of the porcine isolated coronary artery following exposure to lipopolysaccharide. Br J Anaesth 98: 323-330, 2007. (Pubitemid 47072669)
24. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360: 1071-1073, 2002. (Pubitemid 34112540)
25. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155: 1281-1291, 1999. (Pubitemid 29488935)
26. Sherwood D, Edasery J, LeCren G, Cannon PJ. Prostaglandin and HETE synthesis by aortae and hearts of normal and atherosclerotic rabbits. Eicosanoids 4: 29-36, 1991.
27. Stemme V, Swedenborg J, Claesson H, Hansson GK. Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. Eur J Vasc Endovasc Surg 20: 146-152, 2000. (Pubitemid 30649641)
28. Vidal C, Gomez-Hernandez A, Sanchez-Galan E, Gonzalez A, Ortega L, Gomez-Gerique JA, Tunon J, Egido J. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. J Pharmacol Exp Ther 320: 108-116, 2007. (Pubitemid 46025725)
29. Virdis A, Colucci R, Fornai M, Blandizzi C, Duranti E, Pinto S, Bernardini N, Segnani C, Antonioli L, Taddei S, Salvetti A, Del Tacca M. Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric-oxide synthase and oxidative stress. J Pharmacol Exp Ther 312: 945-953, 2005. (Pubitemid 40293752)
30. Wang K, Tarakji K, Zhou Z, Zhang M, Forudi F, Zhou X, Koki AT, Smith ME, Keller BT, Topol EJ, Lincoff AM, Penn MS. Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model. J Cardiovasc Pharmacol 45: 61-67, 2005. (Pubitemid 40039757)
31. Wong E, Huang JQ, Tagari P, Riendeau D. Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis 157: 393-402, 2001. (Pubitemid 32710018)
32. Zhang DX, Gauthier KM, Chawengsub Y, Holmes BB, Campbell WB. Cyclooxygenase- and lipoxygenase-dependent relaxation to arachidonic acid in rabbit small mesenteric arteries. Am J Physiol Heart Circ Physiol 288: H302-H309, 2005. (Pubitemid 40023860)